Aqueous extract of panax notoginseng affecting blood TC, TG and ET-1 levels in postoperative rabbits

Journal of Medicinal Plants Research

Volumn 5, Issue 8, 2011, Pages 1425-1428

  Wang, Yaling ^a   Tang, Jianlin ^a   Pan, Yong ^a   Yang, Tiande ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Carotic artery injury; Postoperative recovery; Rabbit; TC

Indexed keywords

CHOLESTEROL; ENDOTHELIN 1; PANAX NOTOGINSENG EXTRACT; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY INJURY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; MALE; NONHUMAN; POSTOPERATIVE CARE; PROTEIN BLOOD LEVEL; RABBIT; TRIACYLGLYCEROL BLOOD LEVEL;

ORYCTOLAGUS CUNICULUS; PANAX NOTOGINSENG;

EID: 79957687347     PISSN: 19960875     EISSN: 19960875     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. The State Pharmacopoeia Commission of People's Republic of China (2000). Pharmacopoeia of the People's Republic of China vol. 1, Chemical Industry Press, Beijing.
2. Konoshima T, Takasaki M, Tokuda H (1999). Anti-carcinogenic activity of the roots of Panax notoginseng. II, Biol. Pharm. Bull., 22: 1150-1152.
3. Liu SJ, Zhou SW (2000), P. notoginseng saponins attenuated cisplatininduced nephrotoxicity, Acta Pharmacol. Sin., 21: 257-260.
4. Liu J, Liu Y, Klaassen CD (1994). The effect of Chinese hepatoprotective medicines on experimental liver injury in mice, J. Ethnopharmacol., 42: 183-191.
5. Cicero AF, Vitale G, Savino G, Arlett R (2003). P. notoginseng (Burk.) effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet, Phytother. Res., 17: 174-178.
6. Zhang WJ, Wojta J, Binder BR (1994). Effect of notoginsenoside R1 on the synthesis of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells, Arterioscler. Thromb., 14: 1040-1046.
7. Wei JX, Du YC. (1996). Modern Science Research and Application of Panax notoginseng, Yunnan Science and Technology Press, Kunming, China.
8. Ng TB (2006), Pharmacological activity of sanchi ginseng (Panax notoginseng). J. Pharm. Pharmacol., 58: 1007-1019.
9. Wang CZ, McEntee E, Wicks S, Wu JA, Yuan CS (2006). Phytochemical and analytical studies of P. notoginseng(Burk.) FH Chen, J. Nat. Med., 60: 97-106.
10. Ross R (1999). Atherosclerosis-an inflammatory disease. N. Engl. J. Med., 340 (2): 115-126.
11. Zhao HY, Liu FQ, Wang YP, Zhao N, Wu YY, Wang XY (2009). Comparative study of extraction process on the effective components of Panax notoginseng. J. Pharm. Pract., 3: 205-208.
12. Wang L, Folsom AR, Eckfeldt JH (2003). The ARIC Study Investigators. Plasma fatty acid composition and incidence of coronary heart disease in middle aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Nutr. Metab. Cardiovasc. Dis., 13(5): 256-266.
13. Li XC. (1998). Chinese herbal study on anti-ischemia-reperfusion-injury, Chin. J.Hospital Pharm., 154: 1-4.
14. Zhang GQ, Ye RG, Kong QY, Yang NS, Zhang JL, Guan WM, Chen YX (1998). P. notoginsengsaponins induced of human renal interstitial fibroblasts and its mechanisms, Chin. J. Nephrol., 142: 93-99.
15. Zhang YG, Zhang HG, Zhang GY, Fan JS, Li XH, Liu YH, Li SH, Lian XM, Tang Z (2008). P. notoginsengsaponins attenuate atherosclerosis in rats by regulating the blood lipid profile and an anti-inflammatory action. Clin. Exp. Pharmacol. Physiol., 35: 1238-1244.
16. Jouad H, Lemhadri A, Maghrani M, Zeggwagh NA, Eddouks M (2003). Cholesterol-lowering activity of the aqueous extract of Spergularia purpurea in normal and recent-onset diabetic rats. J. Ethnopharmacol, 87(1): 43-49.
17. Haines TH (2001). Do sterols reduce proton and sodium leaks through lipid bilayers?. Prog. Lipid Res., 40(4): 299-324.
18. Lemhadri A, Hajji L, Michel JB, Eddouks M (2006). Cholesterol and triglycerides lowering activities of caraway fruits in normal and streptozotocin diabetic rats. J. Ethnopharmacol., 106(3): 321-326.
19. Cheng DCH, Wolfe BM (1983). Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atheroscler., 46(1): 41-48.
20. Motte S, McEntee K, Naeije R (2006). Endothelin receptor antagonists. Pharmacol. Therapeut., 110(3): 386-414.
21. Belaidi E, Joyeux-Faure M, Ribuot C, Launois SH, Levy P, Godin-Ribuot D (2009). Major Role for Hypoxia Inducible Factor-1 and the Endothelin System in Promoting Myocardial Infarction and Hypertension in an Animal Model of Obstructive Sleep Apnea. J. Am. Coll. Cardiol., 53(15): 1309-1317.